5-alpha Reductase Inhibitors
"5-alpha Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE.
| Descriptor ID |
D058891
|
| MeSH Number(s) |
D27.505.519.389.870.200 D27.505.696.399.450.855.200
|
| Concept/Terms |
5-alpha Reductase Inhibitors- 5-alpha Reductase Inhibitors
- 5 alpha Reductase Inhibitors
- Inhibitors, 5-alpha Reductase
- Reductase Inhibitors, 5-alpha
- Steroid 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Steroid
- Inhibitors, Steroid 5-alpha-Reductase
- Steroid 5 alpha Reductase Inhibitors
- Testosterone 5-alpha-Reductase Inhibitors
- 5-alpha-Reductase Inhibitors, Testosterone
- Inhibitors, Testosterone 5-alpha-Reductase
- Testosterone 5 alpha Reductase Inhibitors
- 3-Oxo-5-alpha-Steroid 4-Dehydrogenase Inhibitors
- 3 Oxo 5 alpha Steroid 4 Dehydrogenase Inhibitors
- 4-Dehydrogenase Inhibitors, 3-Oxo-5-alpha-Steroid
- Inhibitors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
|
Below are MeSH descriptors whose meaning is more general than "5-alpha Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "5-alpha Reductase Inhibitors".
This graph shows the total number of publications written about "5-alpha Reductase Inhibitors" by people in this website by year, and whether "5-alpha Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "5-alpha Reductase Inhibitors" by people in Profiles.
-
5a-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. J Urol. 2022 01; 207(1):183-189.
-
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
-
Effects of 5-alpha reductase inhibitors on lung function: A reason for discontinuation during COVID-19 pandemic? Dermatol Ther. 2020 07; 33(4):e13535.
-
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? Med Hypotheses. 2020 Jul; 140:109751.
-
Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment. Am J Clin Dermatol. 2019 Jun; 20(3):379-390.
-
Finasteride and androgenic alopecia; from therapeutic options to medical implications. J Dermatolog Treat. 2020 Jun; 31(4):415-421.
-
Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatolog Treat. 2019 Sep; 30(6):598-604.
-
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskelet Disord. 2018 May 22; 19(1):160.
-
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan; 32(1):11-22.
-
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease. Exp Neurol. 2017 05; 291:1-7.